{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:54:04Z","timestamp":1790801644317,"version":"4.1.0"},"reference-count":237,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Bortezomib (BTZ) is a first-generation proteasome inhibitor that has shown significant efficacy in the treatment of multiple myeloma (MM), providing significant therapeutic benefits without severely compromising overall patient health. However, one of the most common and debilitating side effects associated with BTZ therapy is bortezomib-induced peripheral neuropathy (BIPN). This condition is the leading complication observed in patients undergoing BTZ treatment and has a profound impact on treatment regimens, often necessitating dose reductions or alterations in the dosing schedule. Despite the widespread recognition of BIPN, therapeutic options remain limited. Consequently, further exploration of the molecular mechanisms underlying BIPN is crucial to identify potential therapeutic targets. Establishing standardized, effective treatment strategies is also essential to improve patient outcomes. This review seeks to provide an in-depth overview of the current research on BIPN, covering its clinical presentation, potential pathophysiological mechanisms, and emerging therapeutic strategies. The aim is to offer valuable insights to support the development of novel therapeutic approaches and enhance clinical management of this challenging side effect.<\/jats:p>","DOI":"10.3389\/fphar.2025.1719384","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:30:11Z","timestamp":1764145811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bortezomib-induced peripheral neuropathy: from molecular mechanisms to clinical management"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuting","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-1466","DOI":"10.12688\/f1000research.8053.1","article-title":"Chemotherapy-induced peripheral neuropathy: an update on the current understanding","volume":"5","author":"Addington","year":"2016","journal-title":"F1000Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1212\/WNL.0000000000012300","article-title":"Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity","volume":"97","author":"Alberti","year":"2021","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.expneurol.2013.12.020","article-title":"Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model","volume":"253","author":"Ale","year":"2014","journal-title":"Exp. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s12640-014-9514-8","article-title":"Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice","volume":"27","author":"Ale","year":"2015","journal-title":"Neurotox. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuro.2016.05.004","article-title":"Inhibition of the neuronal NF\u03baB pathway attenuates bortezomib-induced neuropathy in a mouse model","volume":"55","author":"Ale","year":"2016","journal-title":"Neurotoxicology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5114\/aoms\/114269","article-title":"Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma","volume":"18","author":"Allegra","year":"2022","journal-title":"Arch. Med. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/brain\/awad339","article-title":"Role of pattern recognition receptors in chemotherapy-induced neuropathic pain","volume":"147","author":"Araldi","year":"2024","journal-title":"Brain"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: an update","volume":"88","author":"Argyriou","year":"2014","journal-title":"Arch. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1136\/jnnp-2019-320969","article-title":"Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings","volume":"90","author":"Argyriou","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3988\/jcn.2019.15.4.511","article-title":"Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and A gene polymorphism","volume":"15","author":"Azoulay","year":"2019","journal-title":"J. Clin. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1534735414534729","article-title":"A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma","volume":"13","author":"Bao","year":"2014","journal-title":"Integr. Cancer Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaneurol.2020.2590","article-title":"Patient assisted intervention for neuropathy: Comparison of treatment in real life situations (PAIN-CONTRoLS): Bayesian adaptive comparative effectiveness randomized trial","volume":"78","author":"Barohn","year":"2021","journal-title":"JAMA Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1744806918797042","DOI":"10.1177\/1744806918797042","article-title":"Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain","volume":"14","author":"Bechakra","year":"2018","journal-title":"Mol. Pain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"146621","DOI":"10.1016\/j.brainres.2019.146621","article-title":"Pain-related changes in cutaneous innervation of patients suffering from bortezomib-induced, diabetic or chronic idiopathic axonal polyneuropathy","volume":"1730","author":"Bechakra","year":"2020","journal-title":"Brain Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00520-015-3032-y","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support. Care Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.5114\/wo.2013.37214","article-title":"Bortezomib-induced painful neuropathy in patients with multiple myeloma","volume":"17","author":"Bilinska","year":"2013","journal-title":"Wspolczesna Onkol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"817236","DOI":"10.3389\/fphar.2021.817236","article-title":"Systems pharmacology modeling identifies a novel treatment strategy for bortezomib-Induced neuropathic pain","volume":"12","author":"Bloomingdale","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/14740338.2017.1344212","article-title":"Safety of ixazomib for the treatment of multiple myeloma","volume":"16","author":"Bonnet","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"105952","DOI":"10.1016\/j.nbd.2022.105952","article-title":"Schwann cell functions in peripheral nerve development and repair","volume":"176","author":"Bosch-Queralt","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/fcp.12617","article-title":"An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models","volume":"35","author":"Bouchenaki","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","article-title":"Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice","volume":"223","author":"Bruna","year":"2010","journal-title":"Exp. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-Induced peripheral neuropathy: epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.trsl.2021.01.002","article-title":"Targeting T-type\/CaV3.2 channels for chronic pain","volume":"234","author":"Cai","year":"2021","journal-title":"Transl. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/hon.2391","article-title":"Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients","volume":"36","author":"Campo","year":"2018","journal-title":"Hematol. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e72995","DOI":"10.1371\/journal.pone.0072995","article-title":"Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse","volume":"8","author":"Carozzi","year":"2013","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/cells11081358","article-title":"Ubiquitin proteasome system and microtubules are master regulators of central and peripheral nervous system axon degeneration","volume":"11","author":"Cartelli","year":"2022","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00520-012-1511-y","article-title":"Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma","volume":"20","author":"Cartoni","year":"2012","journal-title":"Support. Care Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpain.2006.09.014","article-title":"Quantitative sensory findings in patients with bortezomib-induced pain","volume":"8","author":"Cata","year":"2007","journal-title":"J. Pain."},{"key":"B33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur. J. Cancer."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","article-title":"Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment","volume":"270","author":"Cebulla","year":"2023","journal-title":"J. Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12974-018-1327-x","article-title":"Reduction of SIRT1 epigenetically upregulates NALP1 expression and contributes to neuropathic pain induced by chemotherapeutic drug bortezomib","volume":"15","author":"Chen","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1345811","DOI":"10.3389\/fnmol.2024.1345811","article-title":"Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy","volume":"17","author":"Chen","year":"2024","journal-title":"Front. Molec. Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12929-018-0448-y","article-title":"Acid-sensing ion channels: dual function proteins for chemo-sensing and mechano-sensing","volume":"25","author":"Cheng","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.3109\/10428194.2015.1023723","article-title":"Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study","volume":"56","author":"Cocito","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.26074","article-title":"Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma","volume":"96","author":"Cook","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients","volume":"34","author":"Corso","year":"2010","journal-title":"Leuk. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"10061","DOI":"10.1038\/s41598-022-13935-2","article-title":"Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients","volume":"12","author":"Dong","year":"2022","journal-title":"Sci. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1111\/bph.14063","article-title":"Characterization of a rat model of bortezomib-induced painful neuropathy","volume":"174","author":"Duggett","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"156494","DOI":"10.1016\/j.phymed.2025.156494","article-title":"Guizhi fuling capsules can alleviate bortezomib-induced peripheral neuropathy by decreasing Interleukin-6 levels to regulate mTOR pathway-induced autophagy","volume":"139","author":"Fu","year":"2025","journal-title":"Phytomedicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1400118","DOI":"10.3389\/fnmol.2024.1400118","article-title":"The dual role of TRPV1 in peripheral neuropathic pain: pain switches caused by its sensitization or desensitization","volume":"17","author":"Gao","year":"2024","journal-title":"Front. Molec. Neurosci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1756-8722-7-41","article-title":"Electroacupuncture for thalidomide\/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study","volume":"7","author":"Garcia","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"113519","DOI":"10.1016\/j.expneurol.2020.113519","article-title":"Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back","volume":"336","author":"Geisler","year":"2021","journal-title":"Exp. Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e129920","DOI":"10.1172\/jci.insight.129920","article-title":"Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program","volume":"4","author":"Geisler","year":"2019","journal-title":"JCI Insight"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1282300","DOI":"10.3389\/fonc.2024.1282300","article-title":"Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma","volume":"14","author":"Geraldes","year":"2024","journal-title":"Front. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neuropharm.2014.08.004","article-title":"Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat","volume":"86","author":"Ghelardini","year":"2014","journal-title":"Neuropharmacology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.expneurol.2016.11.015","article-title":"Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects","volume":"288","author":"Gornstein","year":"2017","journal-title":"Exp. Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8143754","DOI":"10.1155\/2020\/8143754","article-title":"The actions and mechanisms of P2X7R and p38 MAPK activation in mediating Bortezomib-Induced neuropathic pain","volume":"2020","author":"Guo","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13024-024-00757-1","article-title":"Heparin-enriched plasma proteome is significantly altered in Alzheimer\u2019s disease","volume":"19","author":"Guo","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"B58","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/j.pain.0000000000000862","article-title":"Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats","volume":"158","author":"Hamity","year":"2017","journal-title":"Pain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12885-016-3037-z","article-title":"Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma","volume":"17","author":"Han","year":"2017","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s12185-012-1224-5","article-title":"Itraconazole May increase the risk of early-onset bortezomib-induced peripheral neuropathy","volume":"96","author":"Hashimoto","year":"2012","journal-title":"Int. J. Hematol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jphs.2015.09.004","article-title":"Goshajinkigan reduces bortezomib-induced mechanical allodynia in rats: possible involvement of kappa opioid receptor","volume":"129","author":"Higuchi","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e00481","DOI":"10.1016\/j.neurot.2024.e00481","article-title":"Sodium butyrate restored TRESK current controlling neuronal hyperexcitability in a mouse model of oxaliplatin-induced peripheral neuropathic pain","volume":"22","author":"Ho","year":"2025","journal-title":"Neurotherapeutics"},{"key":"B64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41408-024-01034-6","article-title":"Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis","volume":"14","author":"Hoff","year":"2024","journal-title":"Blood Cancer J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.3390\/ijms23073734","article-title":"Specific attenuation of purinergic signaling during bortezomib-induced peripheral neuropathy in vitro","volume":"23","author":"Holzer","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5414\/CP202714","article-title":"Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis","volume":"55","author":"Hu","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1172\/JCI136796","article-title":"Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice","volume":"130","author":"Huang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B68","doi-asserted-by":"publisher","first-page":"12335","DOI":"10.21037\/apm-21-3313","article-title":"Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study","volume":"10","author":"Huang","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.21873\/anticanres.14357","article-title":"Protection of bortezomib-induced neurotoxicity by antioxidants","volume":"40","author":"Iijima","year":"2020","journal-title":"Anticancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.pain.2013.07.032","article-title":"Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase","volume":"154","author":"Janes","year":"2013","journal-title":"Pain"},{"key":"B73","doi-asserted-by":"publisher","first-page":"21082","DOI":"10.1074\/jbc.M114.569574","article-title":"The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1","volume":"289","author":"Janes","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"101502","DOI":"10.1016\/j.redox.2020.101502","article-title":"Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib","volume":"32","author":"Jannuzzi","year":"2020","journal-title":"Redox Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/0271678X16630558","article-title":"Region specific contribution of ASIC2 to acidosis-and ischemia-induced neuronal injury","volume":"37","author":"Jiang","year":"2017","journal-title":"J. Cereb. Blood. Flow. Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/CAD.0b013e32833db89d","article-title":"Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis","volume":"21","author":"Kanbayashi","year":"2010","journal-title":"Anticancer. Drugs."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1172\/JCI26498","article-title":"MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity","volume":"116","author":"Kanda","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.clinph.2017.04.009","article-title":"Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer","volume":"128","author":"Kandula","year":"2017","journal-title":"Clin. Neurophysiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"B80","doi-asserted-by":"publisher","first-page":"16318","DOI":"10.1038\/s41598-018-34507-3","article-title":"Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib","volume":"8","author":"Karademir","year":"2018","journal-title":"Sci. Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jphs.2018.06.008","article-title":"Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro","volume":"137","author":"Kawashiri","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1254\/jphs.13274FP","article-title":"Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice","volume":"124","author":"Kitamura","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/cancers16010084","article-title":"Epigenetic alterations as vital aspects of Bortezomib molecular action","volume":"16","author":"Kulig","year":"2023","journal-title":"Cancers"},{"key":"B84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN guidelines\u00ae insights: multiple myeloma, version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/jnnp-2020-323999","article-title":"Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis","volume":"92","author":"Lambru","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bmj.39192.488125.BE","article-title":"Skin biopsy: a new tool for diagnosing peripheral neuropathy","volume":"334","author":"Lauria","year":"2007","journal-title":"BMJ"},{"key":"B87","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00540-015-2077-x","article-title":"The possible involvement of JNK activation in the spinal dorsal horn in bortezomib-induced allodynia: the role of TNF-\u03b1 and IL-1\u03b2","volume":"30","author":"Li","year":"2016","journal-title":"J. Anesth."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1159\/000495828","article-title":"Blocking TRPA1 and TNF-alpha signal improves Bortezomib-Induced neuropathic pain","volume":"51","author":"Li","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials","volume":"38","author":"Li","year":"2020","journal-title":"Hematol. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pain.2005.02.006","article-title":"Spinal glutamate uptake is critical for maintaining normal sensory transmission in rat spinal cord","volume":"115","author":"Liaw","year":"2005","journal-title":"Pain"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40263-020-00760-2","article-title":"Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study","volume":"34","author":"Lipone","year":"2020","journal-title":"CNS Drugs"},{"key":"B93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbi.2015.11.004","article-title":"Upregulation of CCL2 via ATF3\/c-Jun interaction mediated the bortezomib-induced peripheral neuropathy","volume":"53","author":"Liu","year":"2016","journal-title":"Brain. Behav. Immun."},{"key":"B94","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.expneurol.2018.01.011","article-title":"Upregulation of NLRP3 via STAT3-dependent histone acetylation contributes to painful neuropathy induced by bortezomib","volume":"302","author":"Liu","year":"2018","journal-title":"Exp. Neurol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"845","DOI":"10.33549\/physiolres.934015","article-title":"Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib","volume":"68","author":"Liu","year":"2019","journal-title":"Physiol. Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1007\/s11064-022-03571-7","article-title":"Metformin relieves bortezomib-Induced neuropathic pain by regulating AMPKa2-Mediated autophagy in the spinal dorsal horn","volume":"47","author":"Liu","year":"2022","journal-title":"Neurochem. Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e29626","DOI":"10.7554\/eLife.29626","article-title":"Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy","volume":"6","author":"Lococo","year":"2017","journal-title":"Elife"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.3390\/ijms23052431","article-title":"Bortezomib-induced epigenetic alterations in nerve cells: focus on the mechanisms contributing to the peripheral neuropathy development","volume":"23","author":"Luczkowska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1744806919837429","DOI":"10.1177\/1744806919837429","article-title":"Bortezomib-induced aerobic glycolysis contributes to chemotherapy-induced painful peripheral neuropathy","volume":"15","author":"Ludman","year":"","journal-title":"Mol. Pain"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1744806919850043","DOI":"10.1177\/1744806919850043","article-title":"Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy","volume":"15","author":"Ludman","year":"","journal-title":"Mol. Pain"},{"key":"B102","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.freeradbiomed.2025.09.049","article-title":"Cavidine alleviates paclitaxel-induced peripheral neuropathy by promoting mitochondrial autophagy through inhibiting PKM2-mediated histone lactylation","volume":"241","author":"Luo","year":"2025","journal-title":"Radic. Biol. Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2147\/JPR.S448634","article-title":"Acupuncture in multiple myeloma peripheral neuropathy: a systematic review","volume":"17","author":"Lyu","year":"2024","journal-title":"J. Pain Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1097\/j.pain.0000000000001667","article-title":"Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers","volume":"160","author":"Ma","year":"2019","journal-title":"Pain"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1111\/cas.14178","article-title":"Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma","volume":"110","author":"Maekawa","year":"2019","journal-title":"Cancer Sci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1158\/1078-0432.CCR-15-3163","article-title":"A genome-wide association study identifies a novel locus for bortezomib-Induced peripheral neuropathy in European patients with multiple myeloma","volume":"22","author":"Magrangeas","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1177\/1534735418803758","article-title":"Prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and alpha-lipoic acid in patients with multiple myeloma: preliminary data","volume":"17","author":"Maschio","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/WNF.0000000000000360","article-title":"Role of pregabalin in treatment of polyneuropathy in multiple myeloma patients: a retrospective study","volume":"42","author":"Maschio","year":"","journal-title":"Clin. Neuropharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1534735419888584","DOI":"10.1177\/1534735419888584","article-title":"The effect of docosahexaenoic acid and alpha-lipoic acid as prevention of Bortezomib-Related neurotoxicity in patients with multiple myeloma","volume":"18","author":"Maschio","year":"","journal-title":"Integr. Cancer Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/10428194.2019.1675881","article-title":"The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison","volume":"61","author":"Mateos","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B112","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/life14080991","article-title":"Chemotherapy-induced peripheral neuropathy: a recent update on pathophysiology and treatment","volume":"14","author":"Mattar","year":"2024","journal-title":"Life-Basel"},{"key":"B113","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12974-020-01997-w","article-title":"Spinal neuronal excitability and neuroinflammation in a model of chemotherapeutic neuropathic pain: targeting the resolution pathways","volume":"17","author":"Meesawatsom","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"B114","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fphar.2019.00365","article-title":"Duloxetine, a balanced serotonin-norepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-\u03baB","volume":"10","author":"Meng","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/JPR.S32122","article-title":"CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats","volume":"5","author":"Meregalli","year":"2012","journal-title":"J. Pain Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4161\/cc.27476","article-title":"Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy","volume":"13","author":"Meregalli","year":"2014","journal-title":"Cell Cycle"},{"key":"B117","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12974-018-1270-x","article-title":"High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats","volume":"15","author":"Meregalli","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"B118","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.3390\/cancers13195013","article-title":"Reversal of Bortezomib-Induced neurotoxicity by suvecaltamide, a selective T-Type Ca-Channel modulator, in preclinical models","volume":"13","author":"Meregalli","year":"2021","journal-title":"Cancers"},{"key":"B119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1744-8069-10-9","article-title":"Upregulation of cystathionine-beta-synthetase expression contributes to inflammatory pain in rat temporomandibular joint","volume":"10","author":"Miao","year":"2014","journal-title":"Mol. Pain"},{"key":"B120","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4149\/neo_2022_221007N992","article-title":"Prevention and therapy of chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"70","author":"Michalova","year":"2023","journal-title":"Neoplasma"},{"key":"B121","doi-asserted-by":"publisher","first-page":"104552","DOI":"10.1016\/j.jpain.2024.104552","article-title":"Genetic risk factors for bortezomib-induced neuropathic pain in an Asian population: a genome-wide association study in South Korea","volume":"25","author":"Min","year":"2024","journal-title":"J. Pain."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.clml.2019.08.012","article-title":"Impact of body mass index on the incidence of bortezomib-induced peripheral neuropathy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Moore","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B124","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1182\/blood-2011-05-353995","article-title":"Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment","volume":"118","author":"Morabito","year":"2011","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-pharmtox-010617-052832","article-title":"TRP channels as potential drug targets","volume":"58","author":"Moran","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-019-1461-0","article-title":"Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy","volume":"16","author":"Moschetti","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3389\/fimmu.2020.02119","article-title":"Prokineticin receptor inhibition with PC1 protects mouse primary sensory neurons from neurotoxic effects of chemotherapeutic drugs in vitro","volume":"11","author":"Moschetti","year":"2020","journal-title":"Front. Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12974-022-02454-6","article-title":"The macrophage: a key player in the pathophysiology of peripheral neuropathies","volume":"19","author":"Msheik","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"B132","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11596-018-1844-y","article-title":"Subcutaneous versus intravenous bortezomib administration for multiple myeloma patients: a meta-analysis","volume":"38","author":"Mu","year":"2018","journal-title":"Curr. Med. Sci."},{"key":"B133","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/ph9040070","article-title":"Blocking TRPA1 in respiratory disorders: does it hold a promise?","volume":"9","author":"Mukhopadhyay","year":"2016","journal-title":"Pharmaceuticals"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1111\/bph.13129","article-title":"The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives","volume":"172","author":"Nassini","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/10428194.2019.1678152","article-title":"Prediction of bortezomib-induced peripheral neuropathy with the R-R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study","volume":"61","author":"Nishiwaki","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B136","doi-asserted-by":"publisher","first-page":"116070","DOI":"10.1016\/j.bcp.2024.116070","article-title":"Contributions of neuroimmune interactions to chemotherapy-induced peripheral neuropathy development and its prevention\/therapy","volume":"222","author":"Ollodart","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00018-013-1474-2","article-title":"Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons","volume":"71","author":"Palanca","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"B138","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B139","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/bjh.16446","article-title":"Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis","volume":"189","author":"Parasrampuria","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"Ca. Cancer. J. Clin."},{"key":"B141","doi-asserted-by":"publisher","first-page":"S13-S25","DOI":"10.1111\/jns.12333","article-title":"Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity","volume":"24","author":"Park","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s00520-015-2648-2","article-title":"Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib","volume":"23","author":"Peng","year":"2015","journal-title":"Support. Care Cancer."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e2012685118","DOI":"10.1073\/pnas.2012685118","article-title":"Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy","volume":"118","author":"Pero","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B144","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.19570","article-title":"Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: results of the phase 2 study IFM2014-03","volume":"205","author":"Perrot","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"17143","DOI":"10.3390\/ijms242417143","article-title":"The epigenetics of neuropathic pain: a systematic update","volume":"24","author":"Petho","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B146","doi-asserted-by":"publisher","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition","volume":"7","author":"Poruchynsky","year":"2008","journal-title":"Cell Cycle"},{"key":"B147","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.3390\/ijms25126552","article-title":"Ion channel and transporter involvement in chemotherapy-induced peripheral neurotoxicity","volume":"25","author":"Pozzi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e15994","DOI":"10.1016\/j.heliyon.2023.e15994","article-title":"The nonlinear association between red blood cell distribution width (RDW) and bortezomib-related peripheral neurotoxicity (PN): a retrospective cohort study","volume":"9","author":"Ren","year":"2023","journal-title":"Heliyon"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"","journal-title":"Br. J. Haematol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"","journal-title":"J. Clin. Oncol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"B153","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2217\/fon-2023-0272","article-title":"In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma","volume":"20","author":"Rifkin","year":"2024","journal-title":"Future Oncol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2014.11.009","article-title":"Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy","volume":"285","author":"Robinson","year":"2015","journal-title":"Neuroscience"},{"key":"B155","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.brainres.2014.06.013","article-title":"Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy","volume":"1574","author":"Robinson","year":"","journal-title":"Brain Res."},{"key":"B156","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuroscience.2014.05.051","article-title":"Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat","volume":"274","author":"Robinson","year":"","journal-title":"Neuroscience"},{"key":"B157","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1007\/s00520-018-4618-y","article-title":"High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies","volume":"27","author":"Rossignol","year":"2019","journal-title":"Support. Care Cancer."},{"key":"B158","doi-asserted-by":"publisher","first-page":"11913","DOI":"10.3390\/ijms222111913","article-title":"Interplay between prokineticins and histone demethylase KDM6A in a murine model of Bortezomib-Induced neuropathy","volume":"22","author":"Rullo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B159","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy","volume":"72","author":"Salat","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B160","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"B161","doi-asserted-by":"publisher","first-page":"637593","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/glia.21065","article-title":"Pathological adaptive responses of schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy","volume":"58","author":"Shin","year":"2010","journal-title":"Glia"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1177\/1078155220904153","article-title":"Bortezomib-induced motor neuropathy: a case report","volume":"26","author":"Singh","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B164","doi-asserted-by":"publisher","first-page":"dmm049358","DOI":"10.1242\/dmm.049358","article-title":"Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion","volume":"15","author":"Snavely","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"B165","doi-asserted-by":"publisher","first-page":"2040620719839025","DOI":"10.1177\/2040620719839025","article-title":"Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis","volume":"10","author":"Song","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s42003-023-05624-1","article-title":"Bortezomib-induced neuropathy is in part mediated by the sensitization of TRPV1 channels","volume":"6","author":"Sprague","year":"2023","journal-title":"Commun. Biol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"10880","DOI":"10.1038\/ncomms10880","article-title":"A phosphotyrosine switch regulates organic cation transporters","volume":"7","author":"Sprowl","year":"2016","journal-title":"Nat. Commun."},{"key":"B169","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuro.2013.09.001","article-title":"Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons","volume":"39","author":"Staff","year":"2013","journal-title":"Neurotoxicology"},{"key":"B170","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/cts.12915","article-title":"Role for drug transporters in chemotherapy-induced peripheral neuropathy","volume":"14","author":"Stage","year":"2021","journal-title":"CTS-Clin. Transl. Sci."},{"key":"B171","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Neurosci"},{"key":"B172","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/bph.14215","article-title":"Recent advances in targeting ion channels to treat chronic pain","volume":"175","author":"Stevens","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"key":"B174","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/j.pain.0000000000001697","article-title":"Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents","volume":"161","author":"Stockstill","year":"2020","journal-title":"Pain"},{"key":"B175","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.2217\/fon-2018-0040","article-title":"The role of carfilzomib in treatment of newly diagnosed multiple myeloma","volume":"14","author":"Strifler","year":"2018","journal-title":"Future Oncol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/DDDT.S369111","article-title":"Paeoniflorin ameliorates BiPN by reducing IL6 levels and regulating PARKIN-mediated mitochondrial autophagy","volume":"16","author":"Sun","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"B177","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/OP.22.00781","article-title":"Impact of Black race on peripheral neuropathy in patients with newly diagnosed multiple myeloma receiving bortezomib induction","volume":"19","author":"Sun","year":"","journal-title":"JCO Oncol. Pract."},{"key":"B178","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11064-022-03741-7","article-title":"MiR-672-5p-Mediated upregulation of REEP6 in spinal dorsal horn participates in Bortezomib-Induced neuropathic pain in rats","volume":"48","author":"Sun","year":"","journal-title":"Neurochem. Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1248\/bpb.b22-00861","article-title":"Inhibitors of the mechanistic target of Rapamycin can ameliorate Bortezomib-Induced peripheral neuropathy","volume":"46","author":"Suzuki","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am. J. Hematol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"14287","DOI":"10.1038\/s41598-020-71138-z","article-title":"Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro","volume":"10","author":"Takacs","year":"2020","journal-title":"Sci. Rep."},{"key":"B182","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.3390\/ijms20143411","article-title":"Emerging perspectives on pain management by modulation of TRP channels and ANO1","volume":"20","author":"Takayama","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B183","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1152\/physrev.00005.2019","article-title":"Mammalian transient receptor potential TRPA1 channels: from structure to disease","volume":"100","author":"Talavera","year":"2020","journal-title":"Physiol. Rev."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/tox.24035","article-title":"Evodiamine attenuates oxidative stress and ferroptosis by inhibiting the MAPK signaling to improve bortezomib-induced peripheral neurotoxicity","volume":"39","author":"Tang","year":"2024","journal-title":"Environ. Toxicol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1146\/annurev-neuro-110920-030610","article-title":"Beyond wrapping: canonical and noncanonical functions of schwann cells","volume":"45","author":"Taveggia","year":"2022","journal-title":"Annu. Rev. Neurosci."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1015746","DOI":"10.3389\/fmolb.2022.1015746","article-title":"Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients","volume":"9","author":"Tay","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"B188","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CND.0000000000000077","article-title":"Bortezomib-associated demyelinating neuropathy--clinical and pathologic features","volume":"16","author":"Thawani","year":"2015","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1161077","DOI":"10.3389\/fneur.2023.1161077","article-title":"Abnormal intraepidermal nerve fiber density in disease: a scoping review","volume":"14","author":"Thomas","year":"2023","journal-title":"Front. Neurol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tox.2018.12.003","article-title":"Critical role of Ca(v)3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice","volume":"413","author":"Tomita","year":"2019","journal-title":"Toxicology"},{"key":"B191","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/bph.13652","article-title":"The peptide Ph\u03b11\u03b2, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice","volume":"174","author":"Tonello","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1158\/0008-5472.CAN-12-4370","article-title":"Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade","volume":"73","author":"Trevisan","year":"2013","journal-title":"Cancer Res."},{"key":"B193","doi-asserted-by":"publisher","first-page":"9257","DOI":"10.3390\/ijms22179257","article-title":"Integrated medicine for chemotherapy-induced peripheral neuropathy","volume":"22","author":"Tsai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1177\/1010428318808670","article-title":"Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1\/2 activation","volume":"8","author":"Tsubaki","year":"","journal-title":"Am. J. Cancer Res."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1010428318808670","DOI":"10.1177\/1010428318808670","article-title":"Tamoxifen suppresses paclitaxel-vincristine-and bortezomib-induced neuropathy via inhibition of the protein kinase C\/extracellular signal-regulated kinase pathway","volume":"40","author":"Tsubaki","year":"","journal-title":"Tumour Biol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.3390\/cells10102550","article-title":"Caspase-dependent HMGB1 release from macrophages participates in peripheral neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice","volume":"10","author":"Tsubota","year":"2021","journal-title":"Cells"},{"key":"B197","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/JBM.S44127","article-title":"The protective effects of lafutidine for bortezomib induced peripheral neuropathy","volume":"4","author":"Tsukaguchi","year":"2013","journal-title":"J. Blood Med."},{"key":"B198","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/10428194.2021.1992758","article-title":"Foot drop in patients treated with bortezomib - a case series and review of the literature","volume":"63","author":"Vaxman","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"B199","doi-asserted-by":"publisher","first-page":"S52-S62","DOI":"10.1111\/jns.12338","article-title":"Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Velasco","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B200","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/CAD.0000000000001005","article-title":"Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience","volume":"32","author":"Velasco","year":"2021","journal-title":"Anticancer. Drugs."},{"key":"B201","doi-asserted-by":"crossref","first-page":"453","DOI":"10.36076\/ppj.2021.24.453","article-title":"Treatment impact on patient-reported outcomes in peripheral neuropathic pain: comparing single intervention with topical high-concentration capsaicin to daily oral pregabalin","volume":"24","author":"Viel","year":"2021","journal-title":"Pain Physician"},{"key":"B202","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fnmol.2016.00162","article-title":"Endoplasmic reticulum protein quality control failure in myelin disorders","volume":"9","author":"Volpi","year":"2016","journal-title":"Front. Molec. Neurosci."},{"key":"B203","doi-asserted-by":"publisher","first-page":"e53165","DOI":"10.1371\/journal.pone.0053165","article-title":"Upregulation of cystathionine beta-synthetase expression contributes to visceral hyperalgesia induced by heterotypic intermittent stress in rats","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"B204","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00520-016-3126-1","article-title":"Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib And\/or thalidomide and is associated with severe neuropathy","volume":"24","author":"Wang","year":"2016","journal-title":"Support. Care Cancer."},{"key":"B205","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1158\/1535-7163.MCT-20-0006","article-title":"Dysregulation of EAAT2 and VGLUT2 spinal glutamate transports via histone deacetylase 2 (HDAC2) contributes to paclitaxel-induced painful neuropathy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B206","doi-asserted-by":"publisher","first-page":"836931","DOI":"10.3389\/fncel.2022.836931","article-title":"The effect of Schwann cells\/Schwann cell-like cells on cell therapy for peripheral neuropathy","volume":"16","author":"Wang","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.bjc.6605954","article-title":"Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy","volume":"103","author":"Watanabe","year":"2010","journal-title":"Br. J. Cancer."},{"key":"B208","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1038\/bcj.2013.47","article-title":"Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients","volume":"3","author":"Watanabe","year":"2013","journal-title":"Blood Cancer J."},{"key":"B209","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.expneurol.2017.07.010","article-title":"Activation of RAGE\/STAT3 pathway by methylglyoxal contributes to spinal central sensitization and persistent pain induced by bortezomib","volume":"296","author":"Wei","year":"2017","journal-title":"Exp. Neurol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1002\/alz.13821","article-title":"Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid","volume":"20","author":"Wojtas","year":"2024","journal-title":"Alzheimers. Dement."},{"key":"B211","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/pr.110.002725","article-title":"International union of basic and clinical pharmacology. LXXVI. Current progress in the Mammalian TRP ion channel family","volume":"62","author":"Wu","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00204-023-03468-6","article-title":"Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neurotoxicity","volume":"97","author":"Wu","year":"2023","journal-title":"Arch. Toxicol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.neuropharm.2017.06.027","article-title":"Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord","volume":"123","author":"Xie","year":"2017","journal-title":"Neuropharmacology"},{"key":"B214","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/ijms22020888","article-title":"Pathological mechanisms of Bortezomib-Induced peripheral neuropathy","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B215","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jphs.2015.08.006","article-title":"Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats","volume":"129","author":"Yamamoto","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"B216","doi-asserted-by":"publisher","first-page":"112068","DOI":"10.1016\/j.biopha.2021.112068","article-title":"The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy","volume":"142","author":"Yan","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B217","doi-asserted-by":"publisher","first-page":"20503121231209088","DOI":"10.1177\/20503121231209088","article-title":"Repetitive transcranial magnetic stimulation for chemotherapy-induced peripheral neuropathy in multiple myeloma: a pilot study","volume":"11","author":"Yan","year":"2023","journal-title":"SAGE Open Med."},{"key":"B218","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/00365513.2021.1986857","article-title":"Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study","volume":"81","author":"Yang","year":"2021","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"B219","doi-asserted-by":"publisher","first-page":"e36311","DOI":"10.1016\/j.heliyon.2024.e36311","article-title":"Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review","volume":"10","author":"Yang","year":"","journal-title":"Heliyon"},{"key":"B220","doi-asserted-by":"publisher","first-page":"104353","DOI":"10.1016\/j.critrevonc.2024.104353","article-title":"Bortezomib-induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach","volume":"197","author":"Yang","year":"","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1568009618666181003170027","article-title":"The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of Bortezomib- induced neuropathy","volume":"19","author":"Yin","year":"2019","journal-title":"Curr. Cancer Drug Targets."},{"key":"B222","doi-asserted-by":"publisher","first-page":"e0183491","DOI":"10.1371\/journal.pone.0183491","article-title":"Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies","volume":"12","author":"Youk","year":"2017","journal-title":"PLoS One"},{"key":"B223","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14740338.2024.2393275","article-title":"Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system","volume":"24","author":"Yu","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zajaczkowska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B225","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.seminoncol.2021.09.004","article-title":"Chemotherapy-induced peripheral neuropathy and rehabilitation: a review","volume":"48","author":"Zhang","year":"2021","journal-title":"Semin. Oncol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1471-4159.2006.03746.x","article-title":"Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury","volume":"97","author":"Zhang","year":"2006","journal-title":"J. Neurochem."},{"key":"B227","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbi.2014.01.020","article-title":"TNF-alpha-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy","volume":"38","author":"Zhang","year":"2014","journal-title":"Brain. Behav. Immun."},{"key":"B228","doi-asserted-by":"publisher","first-page":"480","DOI":"10.7534\/j.issn.1009-2137.2017.02.031","article-title":"Prophylaxis of Bortezomib-Induced peripheral neuropathy in patients with multiple myeloma by high-dose intravenous mecobalamin","volume":"25","author":"Zhang","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B229","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1523\/JNEUROSCI.2132-21.2022","article-title":"Fibroblastic SMOC2 suppresses mechanical nociception by inhibiting coupled activation of primary sensory neurons","volume":"42","author":"Zhang","year":"","journal-title":"J. Neurosci."},{"key":"B230","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bbi.2021.12.005","article-title":"An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway","volume":"100","author":"Zhang","year":"","journal-title":"Brain. Behav. Immun."},{"key":"B231","doi-asserted-by":"publisher","first-page":"955","DOI":"10.32604\/or.2023.043922","article-title":"A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients","volume":"32","author":"Zhang","year":"2024","journal-title":"Oncol. Res."},{"key":"B232","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","article-title":"Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy","volume":"238","author":"Zheng","year":"2012","journal-title":"Exp. Neurol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"1744806919863292","DOI":"10.1177\/1744806919863292","article-title":"GATA3-dependent epigenetic upregulation of CCL21 is involved in the development of neuropathic pain induced by bortezomib","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Pain"},{"key":"B234","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1177\/1534735418788667","article-title":"Acupuncture for Bortezomib-Induced peripheral neuropathy: not just for pain","volume":"17","author":"Zhi","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"B235","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40364-023-00490-9","article-title":"Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1","volume":"11","author":"Zhou","year":"","journal-title":"Biomark. Res."},{"key":"B236","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s13311-023-01346-8","article-title":"The therapeutic potential of antioxidants in chemotherapy-induced peripheral neuropathy: evidence from preclinical and clinical studies","volume":"20","author":"Zhou","year":"","journal-title":"Neurotherapeutics"},{"key":"B237","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1756-8722-5-67","article-title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","volume":"5","author":"Zinzani","year":"2012","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1719384\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:30:14Z","timestamp":1764145814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1719384\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":237,"alternative-id":["10.3389\/fphar.2025.1719384"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1719384","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1719384"}}